NASDAQ halts trading in CombinatoRx's common stock

Sep 23 2009NewsGuard 100/100 Score

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee are meeting today, in a public session, to review and discuss the New Drug Application (NDA) of Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, for Exalgo™ (hydromorphone HCI extended release) tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. CombinatoRx and Neuromed entered into a definitive merger agreement on June 30, 2009 for a merger transaction which is expected to close during the fourth quarter of 2009.

The U.S. rights to Exalgo™ were acquired by Mallinckrodt Inc., a subsidiary of Covidien on June 11, 2009.

Source:

CombinatoRx, Incorporated

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

High levels of microplastics found in prostate tumors, possibly linked to take-out food
Frequent ultra-processed food consumption raises mortality risks, especially in women
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Six common flying with food allergies myths
Ultra-processed food linked to weight gain and lower well-being in adolescents
Study finds thousands of food-contact chemicals in humans, raising safety concerns
Limiting fast-food outlets can reduce childhood overweight and obesity
Updated Food Compass 2.0 improves food health ratings using new diet data

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Key triggers for food allergies in children after organ transplants